Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus

NCT00474630 is registered in ClinicalTrials.gov with Orexigen Therapeutics, Inc as lead sponsor.

NCT NCT00474630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00474630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Orexigen Therapeutics, Inc
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2007
Completion date
June 30, 2009
Enrollment
505 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, obesity, overweight